Suga S, Nakao K, Hosoda K, Mukoyama M, Ogawa Y, Shirakami G, Arai H, Saito Y, Kambayashi Y, Inouye K
Department of Medicine, Kyoto University School of Medicine, Japan.
Endocrinology. 1992 Jan;130(1):229-39. doi: 10.1210/endo.130.1.1309330.
To elucidate the ligand-receptor relationship of the natriuretic peptide system, which comprises at least three endogenous ligands, atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP), and three receptors, the ANP-A receptor or guanylate cyclase-A (GC-A), the ANP-B receptor or guanylate cyclase-B (GC-B), and the clearance receptor (C-receptor), we characterized the receptor preparations from human, bovine, and rat tissues and cultured cells with the aid of the binding assay, Northern blot technique, and the cGMP production method. Using these receptor preparations, we examined the binding affinities of ANP, BNP, and CNP for the C-receptor and their potencies for cGMP production via the ANP-A receptor (GC-A) and the ANP-B receptor (GC-B). These analyses revealed the presence of a marked species difference in the receptor selectivity of the natriuretic peptide family, especially among BNPs. Therefore, we investigated the receptor selectivity of the natriuretic peptide family using the homologous assay system with endogenous ligands and receptors of the same species. The rank order of binding affinity for the C-receptor was ANP greater than CNP greater than BNP in both humans and rats. The rank order of potency for cGMP production via the ANP-A receptor (GC-A) was ANP greater than or equal to BNP much greater than CNP, but that via the ANP-B receptor (GC-B) was CNP greater than ANP greater than or equal to BNP. These findings on the receptor selectivity of the natriuretic peptide family provide a new insight into the understanding of the physiological and clinical implications of the natriuretic peptide system.
为阐明利钠肽系统的配体-受体关系,该系统至少包含三种内源性配体,即心房利钠肽(ANP)、脑利钠肽(BNP)和C型利钠肽(CNP),以及三种受体,即ANP-A受体或鸟苷酸环化酶-A(GC-A)、ANP-B受体或鸟苷酸环化酶-B(GC-B)和清除受体(C-受体),我们借助结合测定、Northern印迹技术和cGMP生成方法,对来自人、牛和大鼠组织及培养细胞的受体制剂进行了表征。利用这些受体制剂,我们研究了ANP、BNP和CNP对C-受体的结合亲和力,以及它们通过ANP-A受体(GC-A)和ANP-B受体(GC-B)产生cGMP的效力。这些分析揭示了利钠肽家族在受体选择性方面存在显著的物种差异,尤其是在BNP之间。因此,我们使用同物种内源性配体和受体的同源测定系统,研究了利钠肽家族的受体选择性。在人和大鼠中,对C-受体的结合亲和力排序均为ANP大于CNP大于BNP。通过ANP-A受体(GC-A)产生cGMP的效力排序为ANP大于或等于BNP远大于CNP,但通过ANP-B受体(GC-B)产生cGMP的效力排序为CNP大于ANP大于或等于BNP。利钠肽家族受体选择性的这些发现为理解利钠肽系统的生理和临床意义提供了新的见解。